Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349726 | 0.94 | NPC1 (0.70) | NPC1RAB9ACA1CA2TDP1 | |
| SCHEMBL11900371 | 0.91 | SRD5A2 (0.57) | NPC1RAB9ACA1CA2TDP1 | |
| SCHEMBL13944265 | 0.88 | MEN1 (0.66) | NPC1RAB9ACA1CA2TDP1 | |
| SCHEMBL11900436 | 0.88 | ALDH1A1 (0.53) | NPC1RAB9ACA1CA2TDP1 | |
| Hydrochloric Acid SCHEMBL4193255 | 0.86 | MEN1 (0.69) | NPC1RAB9ACA1CA2TDP1 | |
| SCHEMBL27682680 | 0.82 | HSD17B10 (0.53) | NPC1RAB9ATSHRALDH1A1KDM4E | |
| SCHEMBL1065115 | 0.80 | TSHR (0.53) | NPC1RAB9ACA1CA2TDP1 | |
| SCHEMBL28993944 | 0.80 | CA1 (0.80) | NPC1RAB9ACA1CA2TDP1 | |
| SCHEMBL23600 | 0.80 | CA1 (0.80) | NPC1RAB9ACA1CA2TDP1 | |
| SCHEMBL5350433 | 0.80 | NPC1 (0.89) | NPC1RAB9ACA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
| CN-107922347-A | New imide derivative and its purposes as medicine | 田边三菱制药株式会社 | 2018-04-17 | — | — | CN | disclosed |
| US-9540360-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-10 | — | — | US | disclosed |
| EP-2686302-B1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| US-8987445-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2686302-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140005393-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | KALLYOPE, INC. | 2014-01-02 | — | — | US | disclosed |
| CN-103443080-A | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORP | 2013-12-11 | — | — | CN | disclosed |
| WO-2012124825-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | TRPM8, TRPM7, TRPM2 | NPC1 2033/4885RAB9A 2011/4885CA1 454/4885 |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | NPC1 4881/4885RAB9A 270/4885CA1 1423/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | NPC1 4882/4885RAB9A 345/4885CA1 1245/4885 |
| US-20140005393-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | TRPM8, TRPM7, TRPM2 | NPC1 1731/4885RAB9A 1931/4885CA1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.